Phase 2 N=32 Bevacizumab in Treating Patients With Angiosarcoma
Sarcoma
Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: PFS Rate — 54.6 percentage of patients
Phase 2 N=31 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Progression-Free Survival (PFS) at 4 Months — 52.17 percentage of patients alive
Phase 3 N=128 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Advanced Angiosarcoma
Primary: Progression Free Survival of Patients With Unresectable Angiosarcoma — 4.2; 4.3; 3.5; 2.9 months
Phase 2 N=16 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Confirmed Response Rate (CR or PR) Using RECIST — 0 percentage of participants
Phase 2 N=20 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants
Phase 2 N=34 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=51 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Phase 2 N=24 Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Phase 2 N=111 A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 3; 1; 22 Participants
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=53 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
Phase 2 N=12 Alimta Plus Gemcitabine for Advanced Sarcoma
Sarcoma, Soft Tissue
Primary: Tumor Best Response Rate — 0 Participants
Phase 2 N=10 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases
Synovial Sarcoma · Single or Multiple Lung Metastases
Primary: Number of Participants Evaluated for Toxicity — 10 Participants
Phase 2 N=55 Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Refractory Soft Tissue Sarcomas
Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants
Phase 2 N=63 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Fallopian Tube Cancer · Female Reproductive Cancer · Ovarian Carcinosarcoma
Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 1 N=9 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Sarcoma
Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants
Phase 2 N=8 Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Phase 2 N=61 Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants